Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $38 from $41 and keeps an Outperform rating on the shares. Dyne faces a slight delay in U.S. site activation, pushing back the completion of its registrational cohort enrollment to 2Q26, the analyst tells investors in a research note. Despite this, the firm noted that nearly half of the study is already enrolled, and there’s no specific requirement for U.S.-based participants.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target raised to $46 from $38 at H.C. Wainwright
- Positive Outlook for Dyne Therapeutics: Strong Financial Performance and Promising Clinical Developments Support Buy Rating
- Dyne Therapeutics Advances in Neuromuscular Disease Therapies
- Dyne Therapeutics reports Q3 EPS (76c), consensus (85c)
- Dyne Therapeutics announces Z-rostudirsen remains on track for 1Q27 launch